Drugs / HSK42360
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07158710 | Aug 2025 → May 2029 expected | brain cancer | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06536400 | Jun 2024 → Aug 2026 overdue | cancer | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK42360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07158710 ↗ |
| Route | Oral | “given orally” NCT06536400 ↗ |